Signum Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Signum Biosciences, Inc. - overview
Established
2003
Location
Boulder, CO, US
Primary Industry
Biotechnology
About
Based in Colorado, US, and founded in 2003 by Chief Executive Officer Jeffry Stock, Signum Biosciences, Inc. operates as a biopharmaceutical company providing lipid signal transduction modulators (STMs) for chronic neurodegenerative and inflammatory diseases. In April 2007, Signum Biosciences, Inc. raised USD 1 million in Series A funding from New Jersey Economic Development Authority.
Signum Biosciences, Inc. developed SIG1459, which is a phytyl-cysteine derived TLR2 modulator with in vitro and clinical anti-acne activity. It provides SIG-1191, SIG-1191TM, and SIG-1191, which are developed through hydrating cosmetic functional ingredient for suborbital hyperpigmentation and improving expression of the aquaglyceroporin, aquaporin-3, in human. The company offers synergistic neuroprotection, eicosanoyl-5-hydroxytryptamide (EHT), and many more.
The firm focuses on treating regulatory dysfunctions underlying Alzheimer's, Parkinson's, Rosacea, Psoriasis and other diseases.
Current Investors
New Jersey Economic Development Authority
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Dermatology, Pharmaceutical Research & Development
Website
www.signumbio.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.